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Abstract
Setting: A South African township clinic where loss to follow-up during TB treatment may prevent HIV-infected TB patients
from receiving life-saving ART.
Objective: To determine factors associated with loss to follow-up during TB treatment.
Design: Regression analyses of a cohort of ART-eligible TB patients who commenced TB treatment and were followed for
24 weeks.
Results: Of 111 ART-eligible TB patients, 15 (14%) died in the ensuing 24 weeks. Of the remaining 96 TB patients, 11 (11%)
were lost to follow-up. All TB patients lost to follow-up did not initiate ART. Of 85 TB patients in follow-up, 62 (73%) initiated
ART 56 days after TB diagnosis (median, IQR 33–77 days) and 31 days after initial assessment at an ART clinic (median, IQR:
18–55 days). The median duration from TB diagnosis to initial assessment at an ART clinic was 19 days (IQR: 7–48 days). At
24 weeks, 6 of 85 (7%) TB patients who presented to an ART clinic for assessment were lost to follow-up, compared to 5 of
11 (45%) TB patients who did not present to an ART clinic for assessment. Logistic regression analysis (adjusted odds ratio
= 0.1, 95% confidence interval [95% CI]: 0.03–0.66) and our Cox proportional hazards model (hazard ratio = 0.2, 95% CI:
0.04–0.68) confirmed that assessment at an ART clinic during TB treatment reduced loss to follow-up.
Conclusion: Assessment at antiretroviral clinics for HIV care by trained health-care providers reduces loss to follow-up
among HIV-infected patients with TB.
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Introduction
In sub-Saharan Africa, tuberculosis (TB) is the most frequent
cause of death in HIV-1 infected adults [1]: between 8% and 23%
of HIV-infected TB patients die during TB treatment. [2,3] The
initiation of antiretroviral treatment (ART) during TB treatment
among those with severe immune-suppression improves survival.
[4] In HIV-infected TB patients with CD4 counts less than 50
cells/microL, initiation of ART 1–3 weeks after commencing TB
treatment reduces mortality and/or the development of AIDS by
34–68%, compared to initiating ART later during TB treatment.
[5–7].
Thus, timely initiation of ART during TB treatment is a
priority. However, TB patients co-infected with HIV typically
attend completely separate HIV and TB clinics in different
localities. [8] Up to 9% of HIV-infected TB patients are lost to
follow-up during TB treatment, [9,10] precluding initiation of
ART. Identifying those at risk of loss to follow-up is essential. In
this study, we performed a secondary analysis of a recently
described prospective cohort of HIV-infected TB patients [11,12]
in order to determine factors associated with loss to follow-up
during TB treatment.
Methods
Study Population
We conducted our study in a high density (.7500 inhabitants/
km2), predominantly black African township in South Africa, [13]
where annual TB case notification rates approach 1,600/
100,000 people of the general population. TB patients in this
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township are treated in TB clinics administered by Cape Town’s
Health Department. According to national protocol, TB patients
receive standardized TB treatment regimens using Directly
Observed Therapy Short-course (DOTS). [14] National guidelines
at the time of our study recommended ART for all TB patients
with a CD4+ cell count less than 200 cells/mL or a history of a
WHO stage 4 illness. [14] Extra-pulmonary TB – although a
World Health Organisation (WHO) stage 4 illness – was not an
indication for ART unless the patient’s CD4+ count was less than
200 cells/mL. First-line ART during our study was stavudine,
lamivudine, and either nevirapine or efavirenz. Efavirenz was
preferred for adults receiving rifampin-based TB treatment.
National guidelines also recommended daily trimethoprim-sulfa-
methoxazole (160/800mg) chemoprophylaxis. [14].
Our study center is one of the first in South Africa to
successfully integrate HIV and TB healthcare services. As a result,
our TB cohort is characterised by high rates of i) voluntary
counselling and testing of HIV status (.95%), ii) rigorous testing
of CD4+ counts if HIV-infected (.99%), and iii) provision of
trimethoprim-sulfamethoxazole chemoprophylaxis (.95%). [11]
Moreover, DOTS coverage is .80% at this center (personal
communication – Judy Caldwell, Cape Town Health Depart-
ment).
We have previously described our prospective cohort of 209
HIV-infected TB patients ($18 years of age), which we recruited
at our study center. Data obtained from this cohort was used to
determine the incidence, risk factors, and causes of clinical
deterioration during 6 months of TB therapy, [10] as well as
identify barriers to initiation of ART during TB treatment. [11]
All adults in our cohort were recruited at initiation of TB therapy
– regardless of HIV status – and followed for 6 months. Written
informed consent was obtained from enrolled adults and the
Research Ethics Committee of the University of Cape Town
approved this study (REC 178/2008).
The following is a secondary analysis of this cohort: among
those eligible to receive ART, we determined factors associated
with loss to follow-up. Of 209 enrolled HIV-infected TB patients
(figure 1), 111 comprised our study population as they were eligible
to initiate ART at TB diagnosis according to national guidelines.
Reasons for excluding the remaining 98 TB patients are shown in
figure 1: CD4+ count not performed (n = 3), ART started prior to
TB treatment (n = 33), transferred out (n = 13), and ineligible for
ART as CD4+ count greater than 200 cells/mL (n= 49). Of the
111 eligible adults (figure 1), 15 (14%) died, 11 (10%) were lost to
follow-up, and 85 (76%) were alive and under our care at 24 weeks
of follow-up. We defined ‘transferred out’ as transfer of care to
another tuberculosis clinic at a patient’s request. This transfer was
facilitated by a written referral letter and resulted in exclusion from
our study. We defined ‘lost to follow-up’ as being unable to trace a
TB patient 24 weeks after commencing TB treatment. Patients not
lost to follow-up were alive and under our care at 24 weeks of
follow-up. We used clinic and hospital charts, as well as the
Provincial Government of the Western Cape’s electronic tuber-
culosis register (ETR.net), [15] to trace TB patients and record
clinical outcomes.
We determined the proportion of eligible TB patients lost to
follow-up during TB treatment. In our setting, integration of TB
and HIV services is the goal. As such, ART-eligible TB patients
were referred with a written letter to their nearest ART clinic for
assessment. TB patients who presented to the ART clinic for
assessment received ART education from trained counsellors.
After appropriate counselling and evaluation by either a nurse or
doctor, TB patients initiated ART. In our study, a TB patient who
attended one or more ART clinic appointment(s) was considered
to have ‘presented to an ART clinic for assessment.’ We reviewed
TB patients’ hospital and ART charts, the Western Cape’s
electronic tuberculosis register (ETR.net) [15] and Cape Town’s
electronic eKapa ART database to record those who presented to
an ART clinic for assessment, as well as those who initiated ART.
We defined clinical deterioration as symptomatic worsening or
failure to stabilise within 24 weeks following initiation of TB
treatment. [11] Causes of clinical deterioration included AIDS-
defining illnesses (according to WHO stage 4 criteria), non AIDS-
defining HIV-related infections, TB-related illnesses, and illnesses
unrelated to TB, i.e. co-morbid illnesses. These illnesses have been
described in detail in a previous report. [11].
Statistical Analysis
We performed statistical analysis using Stata 10.0 (Texas, USA).
We found that age, weight at TB diagnosis, and duration from
commencing TB treatment to ART initiation were right (non-
normal) skewed but had normal distributions with logarithmic
transformation (Shapiro-Wilk test); the mean age was used to
dichotomise age categories (age ,36 years vs age .36 years).
Proportions were calculated for categorical variables and described
using 95% confidence intervals (CI). We used Fisher’s exact test to
determine which categorical variables were significantly associated
with loss to follow-up. A p-value of less than 0.05 was considered
significant.
Using logistic regression analysis, we explored relationships
between significant variables and loss to follow-up. A backward
stepwise logistic model was proposed to quantify these relation-
ships, which were reported using odds ratios and 95% CI (table 1).
We fitted the model using the likelihood ratio, which was
logarithmically transformed to generate the chi-squared statistic.
Those lost to follow-up had a shorter period of follow-up, so we
created a Cox proportional hazards model to assess the
independent effects of covariates. A backward stepwise model
was proposed and variables were removed from the model to
assess whether the effects remained (table 2). The assumptions of
the Cox model were verified: censoring was non-informative and
the tests for the proportional hazards assumption were not
significant.
Results
Description of TB Patients
Among the 96 TB patients eligible for analysis, the mean age
was 36 years (95% CI: 22–57 years) and 50% were male (Table 1).
At TB diagnosis, 65% of TB patients had a CD4+ count
,100 cells/mL, 26% had a previous history of TB, and 43% had
extra-pulmonary TB (with or without co-existent pulmonary TB).
In 27% of TB patients, results for TB drug susceptibility testing
were known at TB diagnosis. During TB treatment, 95% of TB
patients received trimethoprim-sulfamethoxazole chemoprophy-
laxis, 57% experienced clinical deterioration and 41% required
hospital admission. 85 of 96 (89%) TB patients were alive and in
care at completion of TB treatment, 79 of whom were assessed at
an ART clinic within 19 days of TB diagnosis (median,
interquartile range: 7–48 days). Eleven of 96 (11%) TB patients
were lost to follow-up 68 days (median, interquartile range: 64–
128 days) after commencing TB treatment; 5 of these patients
were not assessed at an ART clinic and all did not initiate ART.
Of the 85 TB patients in follow-up, 62 (73%) initiated ART
56 days after TB diagnosis (median, IQR: 33–77 days) and
31 days after initial assessment at an ART clinic (median,
IQR:18–55 days). 23 of 85 (27%) TB patients in follow-up did
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not initiate ART. Overall, 34 of 96 (35%) eligible TB patients did
not initiate ART during TB treatment.
Risk Factors for Loss to Follow-up
At 24 weeks of follow-up, 7% (6/85) of adults who presented to an
ART clinic for assessment were lost to follow-up, compared to 45%
(5/11) of those who did not present to an ART clinic. In univariate
analyses, the following were significantly associated with loss to
follow-up: not receiving trimethoprim-sulfamethoxazole chemopro-
phylaxis, knowing the results for TB drug susceptibility testing at TB
diagnosis, not presenting to an ART clinic for assessment, and not
initiating ART. All TB patients who were lost to follow-up did not
initiateART,while73%(62of85)ofTBpatients in follow-upinitiated
ART. Using our logistic regression model (P = 0.023, R2= 0.2147),
we found that presentation to an ART clinic for assessment was the
only factor associated with decreased loss to follow-up (odds ratio
= 0.1, 95%CI: 0.03–0.66, table 2). Our Cox proportional hazards
model (P = 0.025, Harrell’s C=0.791, Somers’ D= 0.582) con-
firmed this significant association (hazard ratio = 0.2, 95%CI: 0.04–
0.68, table 3). Figure 2 is aKaplan-Meier plot, which shows that from
12 weeks of follow-up onward, a significant and distinct trend
emerged for loss to follow-up according to whether patients were
assessed at an ART clinic or not.
Discussion
We conducted a retrospective analysis of a cohort of HIV-
infected TB patients eligible for ART while receiving TB
treatment. We found that loss to follow-up occurred in 11% of
TB patients eligible for ART. We also found that assessment at an
ART clinic during TB treatment reduced loss to follow-up. Our
findings have important implications for TB and ART policy-
makers in Africa: the trends we report suggest that interventions to
reduce loss to follow-up should be implemented during TB
treatment, preferably within the first three months. Our findings
resonate with a recent South African study, which reported a trend
in reduction of loss to follow-up among patients initiating ART at
CD4 counts less than 200 cells/mL. [16].
Our findings are best interpreted in the following context:
compared to other clinics in South Africa, the Khayelitsha Site B
TBclinicbenefits fromstrongpartnerships thatexistbetweentheCity
ofCapeTown, theDepartment ofHealthand thenon-governmental
organisationMe´decins Sans Frontieres.TheSiteBTBclinic has received
numerous accolades for pioneering the integration of HIV and TB
services in South Africa. However, despite significant achievements,
such as voluntary counselling and testing of HIV status in.95% of
TB patients, drug susceptibility testing on almost all bacteriologic
specimens during the study period, and trimethoprim-sulfamethox-
Figure 1. Flow-diagram showing inclusion criteria and outcomes of 111 patients eligible for antiretroviral treatment at TB
diagnosis. ART: antiretroviral treatment, TB: tuberculosis.
doi:10.1371/journal.pone.0037634.g001
Table 1. Description of Tuberculosis Patients.
n (%)
Male gender 48 (50)
Age ,36 years 56 (58)
CD4+ count ,100 cells/mL 62 (65)
TMP-SMX chemoprophylaxis 91 (95)
Previous TB 25 (26)
Diagnosis of TB at hospital 46 (48)
Extra-pulmonary TB 41 (43)
Drug susceptibility test results known at TB diagnosis 26 (27)
Weight less than 50 kilograms 27 (28)
Assessed at ART clinic 85 (89)
ART initiated during TB treatment 62 (65)
Experienced clinical deterioration 55 (57)
Admission to hospital 39 (41)
LTF: loss to follow-up, ART: antiretroviral treatment, TB: tuberculosis, TMP-SMX
chemoprophylaxis: daily trimethoprim sulfamethoxazole chemoprophylaxis
160/800mg.
doi:10.1371/journal.pone.0037634.t001
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azole chemoprophylaxis in .95% of HIV-1 infected patients, [11]
loss to follow-up remains a significant challenge.
The substantial proportion of patients lost to follow-up (11%) is
similar to reported rates in the international literature, in which up
to 9% of HIV-infected patients are lost to follow-up during TB
treatment. [9,10] Among HIV-infected patients (with or without
TB), loss to follow-up during ART is similar, varying between 2–
13%. [17,18] One of the strengths of our study is that we
determined modifiable risk factors for loss to follow-up, which are
typically difficult to ascertain. Using multivariate analysis, which
incorporated a number of demographic, HIV, TB, and opera-
tional factors, we found that loss to follow-up was associated with i)
not presenting to an ART clinic for assessment, and ii) not
initiating ART (the latter in univariate analysis, which was
subsequently excluded from our multivariate model due to
collinearity). It is not known whether loss to follow-up resulted
in patients not receiving ART, or whether the failure to initiate
ART in these patients resulted in loss to follow-up. It is certainly
plausible that ART initiation improves follow-up: in adults who
suffer life-threatening illnesses due to profound immune-suppres-
sion, the initiation of ART not only improves immune function,
survival, and well-being, but also promotes regular ART clinic
attendance. Moreover, ART clinics offer an additional safety net
of counselling and medical support. Other studies have demon-
strated the benefit of co-treatment: ART with TB treatment
increases retention during follow-up, compared to ART alone.
[19] Likewise, in our study, we found that attending an ART clinic
during TB treatment was independently associated with improved
follow-up, compared to TB treatment alone.
We acknowledge that while we were able to determine risk
factors for loss to follow up, we were not able to elucidate the
underlying reasons for loss to follow up. In our setting, the
following obstacles impair this investigation: i) most patients reside
in informal housing (‘shacks’), the addresses of which are
vulnerable to change with inclement weather and renovation; ii)
cellular/mobile telephones are the preferred method of contacting
adults in informal housing, but these telephones are subject to
frequent exchange, theft and loss; and iii) the dynamic flux of
people between Cape Town and the Eastern Cape Province
(1000km eastward of Cape Town) hampers data collection, as
patients may travel to the Eastern Cape Province and receive
health care or die there. Future studies are needed to determine
reasons for loss to follow-up. As described previously, twenty-four
weeks of follow-up is a short period of observation. [11] It is
possible that after 24 weeks, other factors may be associated with
loss to follow-up. Of concern, a substantial proportion of TB
patients (17/85, 20%) who presented to an ART clinic and
remained in care did not initiate ART during TB treatment.
Reasons for these delays also require further evaluation.
Furthermore, based on our findings, we have expanded our TB-
ART care so that each HIV-infected patient with tuberculosis has
one folder and is assessed at each appointment by a doctor or
nurse who is skilled in the care of both diseases. This method has
ensured that appropriate HIV care and assessment for ART is
provided at the initial tuberculosis encounter.
Conclusion
The benefits of attending an ART clinic during TB treatment
appear multifaceted: ART initiation during TB treatment reduces
mortality, and care within an ART clinic reduces loss to follow-up.
We therefore recommend that all HIV-infected adults eligible for
ART and receiving TB treatment be assessed at ART clinics as
soon as possible for initiation of ART. For those with CD4+ counts
,50 cells/mL who need to initiate ART within 2 weeks of
commencing TB treatment,[5–7] immediate (same day) referral
for ART assessment and expedited assessment for ART is needed.
Early assessment for HIV care by a trained health care provider is
also essential. ART initiation during TB treatment reduces
mortality and loss to follow-up among HIV-infected adults.
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Table 2. Univariate analyses and logistic regression model showing variables associated with loss to follow-up during TB
treatment.
OR 95% CI aOR 95% CI
Age ,36 years 1.23 (0.35–4.34) 1.75 (0.36–8.40)
TMP-SMX chemoprophylaxis 0.16 (0.02–1.12) 0.25 (0.02–2.80)
Extra-pulmonary TB 0.46 (0.12–1.87) 1.13 (0.20–6.48)
Drug susceptibility test results known at TB diagnosis 3.90 (1.08–14.2) 3.19 (0.63–16.2)
Assessed at ART clinic 0.09 (0.02–0.39) 0.14 (0.03–0.66)
ART initiated during TB treatment 0.01 (0.01–0.17) – –
Experienced clinical deterioration 0.38 (0.10–1.40) 0.61 (0.14–2.65)
ART: antiretroviral treatment, TB: tuberculosis, TMP-SMX chemoprophylaxis: daily trimethoprim sulfamethoxazole chemoprophylaxis 160/800mg.
For this logistic regression model: P = 0.023, R2 = 0.2147, ART initiation was a collinear variable so was omitted from analysis.
doi:10.1371/journal.pone.0037634.t002
Table 3. Cox Proportional Hazards Model for loss to follow-
up during TB treatment.
aHR 95% CI
Age ,36 years 1.73 (0.44–6.74)
TMP-SMX chemoprophylaxis 0.33 (0.06–1.80)
Extra-pulmonary TB 0.97 (0.20–4.67)
Drug susceptibility test results known at TB diagnosis 2.17 (0.53–8.87)
Assessed at ART clinic 0.17 (0.04–0.68)
Experienced clinical deterioration 0.92 (0.22–3.84)
ART: antiretroviral treatment, TB: tuberculosis, TMP-SMX chemoprophylaxis:
daily trimethoprim sulfamethoxazole chemoprophylaxis 160/800mg.
For this Cox proportional hazards model: P = 0.025, Harrell’s C = 0.791, Somers’
D = 0.582, ART initiation was a collinear variable so was omitted from analysis.
doi:10.1371/journal.pone.0037634.t003
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